Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Masamichi Mizuma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6436-5477; OpenAlex author ID A5027803701. Sources: OpenAlex.

Their work

Papers
73 (first author 20, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
220
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 4 papers · 2017: 6 papers · 2018: 1 paper · 2019: 5 papers · 2020: 6 papers · 2021: 11 papers · 2022: 5 papers · 2023: 9 papers · 2024: 3 papers · 2025: 9 papers · 2026: 9 papers

Papers 50 of 73

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.1810↗
  2. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
  3. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  4. Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database. Co-author DOI 10.1007/s00535-026-02480-8↗
  5. Histological treatment response to neoadjuvant chemotherapy predicts the survival outcomes of patients with resectable pancreatic cancer: validation of the Jap… Co-author DOI 10.1007/s00595-026-03325-w↗
  6. Long-term outcomes of plastic versus metal stents for preoperative biliary drainage in pancreatic cancer: a nationwide propensity score-matched analysis. Co-author DOI 10.1016/j.gie.2026.05.032↗
  7. SMAD3 activation in pancreatic stellate cells correlates with PTGDR2 expression and favorable stromal features in pancreatic cancer. Co-author DOI 10.1016/j.pan.2026.03.007↗
  8. Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study Using the Japan Pancreatic Cancer Registry. Co-author DOI 10.1097/mpa.0000000000002694↗
  9. Predictive Factors for Occult Metastases in Clinically M0 Pancreatic Cancer: A Prospective Multicenter Analysis of Staging Laparoscopy. Co-author DOI 10.1245/s10434-026-20728-8↗
  10. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  11. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… First author DOI 10.1002/jhbp.12074↗
  12. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  13. A case of FGFR2 fusion-positive pancreatic head tumor with difficult differential diagnosis between cholangiocarcinoma and pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12328-025-02193-0↗
  14. Transcriptional regulation of ETV5 by mitogen-activated protein kinase via ETS-1 in human pancreatic cancer cells. Co-author DOI 10.1038/s41598-025-97166-1↗
  15. Preoperative Chemotherapy With Gemcitabine for Pancreatic Cancer Causes Zinc Deficiency. First author DOI 10.1097/mpa.0000000000002396↗
  16. Local Recurrence and Survival Outcomes after Portal Vein/Superior Mesenteric Vein Separation without Resection Preceding Neoadjuvant Therapy for Pancreatic Duc… First author DOI 10.1097/mpa.0000000000002503↗
  17. [Multidisciplinary treatment for unresectable pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.122.819↗
  18. Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18084-0↗
  19. GFPT2 expression is induced by gemcitabine administration and enhances invasion by activating the hexosamine biosynthetic pathway in pancreatic cancer. Co-author DOI 10.1007/s10585-024-10298-y↗
  20. Deep learning predicts the 1-year prognosis of pancreatic cancer patients using positive peritoneal washing cytology. Co-author DOI 10.1038/s41598-024-67757-5↗
  21. Machine Learning of Histopathological Images Predicts Recurrences of Resected Pancreatic Ductal Adenocarcinoma With Adjuvant Treatment. Co-author DOI 10.1097/mpa.0000000000002289↗
  22. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical … First author DOI 10.1002/jhbp.1282↗
  23. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  24. GATA6 and CK5 Stratify the Survival of Patients With Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1016/j.modpat.2023.100102↗
  25. Negative prognostic impact of sarcopenia before and after neoadjuvant chemotherapy for pancreatic cancer. First author DOI 10.1016/j.pan.2022.11.010↗
  26. Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectab… First author DOI 10.1016/j.pan.2023.07.002↗
  27. Collagen XVII regulates tumor growth in pancreatic cancer through interaction with the tumor microenvironment. Co-author DOI 10.1111/cas.15952↗
  28. Reduced expression of phosphorylated ataxia-telangiectasia mutated gene is related to poor prognosis and gemcitabine chemoresistance in pancreatic cancer. Co-author DOI 10.1186/s12885-023-11294-3↗
  29. CA19-9 With Two-stage Resection Is Useful for Conversion Surgery in PDAC With Synchronous Oligometastases. First author DOI 10.21873/anticanres.16724↗
  30. [A Case of an Elderly Patient Who Underwent Conversion Resection for Pancreatic Cancer with Positive Peritoneal Cytology]. Co-author PMID 36807179↗
  31. Levels of tumor markers CEA/CA 19-9 in serum and peritoneal lavage predict postoperative recurrence in patients with pancreatic cancer. Co-author DOI 10.1002/ags3.12597↗
  32. What is the impact of zinc deficiency for pancreatectomies in patients with pancreatic ductal adenocarcinoma? First author DOI 10.1016/j.pan.2021.12.006↗
  33. Prognostic impact of postoperative infection in patients with pancreatic cancer: A multicenter cohort study. Co-author DOI 10.1016/j.surg.2022.09.002↗
  34. Comparison of acute gastrointestinal toxicities between 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy including prophylactic region… Co-author DOI 10.1093/jrr/rrac049↗
  35. Impact of Tumor-Derived DNA Testing in Peritoneal Lavage of Pancreatic Cancer Patients with and Without Occult Intra-Abdominal Metastases. Co-author DOI 10.1245/s10434-021-10997-w↗
  36. Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese… First author DOI 10.1002/ags3.12482↗
  37. Circulating tumor DNA as a predictive marker for occult metastases in pancreatic cancer patients with radiographically non-metastatic disease. First author DOI 10.1002/jhbp.993↗
  38. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Co-author DOI 10.1007/s00595-020-02121-4↗
  39. Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery fo… Co-author DOI 10.1007/s00595-021-02279-5↗
  40. Silencing of LRRFIP1 enhances the sensitivity of gemcitabine in pancreatic cancer cells by activating JNK/c-Jun signaling. Co-author DOI 10.1016/j.pan.2021.02.018↗
  41. Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer. Co-author DOI 10.1038/s41598-021-86099-0↗
  42. MicroRNA-593-3p Expression in Peritoneal Lavage Fluid as a Prognostic Marker for Pancreatic Cancer Patients Undergoing Staging Laparoscopy. First author DOI 10.1245/s10434-020-09440-3↗
  43. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up… First author DOI 10.1245/s10434-021-09718-0↗
  44. ASO Author Reflections: Preceding Systemic Chemotherapy Might Provide Better Prognosis for Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology. First author DOI 10.1245/s10434-021-09755-9↗
  45. Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a P… Co-author DOI 10.3389/fonc.2021.646141↗
  46. Stomatin‑like protein 2 induces metastasis by regulating the expression of a rate‑limiting enzyme of the hexosamine biosynthetic pathway in pancreatic cancer. Co-author DOI 10.3892/or.2021.8041↗
  47. Prognostic indicators in pancreatic cancer patients undergoing total pancreatectomy. Co-author DOI 10.1007/s00595-019-01924-4↗
  48. Impact of a board certification system and implementation of clinical practice guidelines for pancreatic cancer on mortality of pancreaticoduodenectomy. Co-author DOI 10.1007/s00595-020-02017-3↗
  49. CD109 promotes the tumorigenic ability and metastatic motility of pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1016/j.pan.2020.01.013↗
  50. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. First author DOI 10.1016/j.pan.2020.08.022↗

Closest collaborators

The 25 strongest of 220 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michiaki Unno · 65 shared papers, 2013–2026 · strength 9.06
  2. Kei Nakagawa · 36 shared papers, 2013–2025 · strength 4.47
  3. Fuyuhiko Motoi · 38 shared papers, 2013–2026 · strength 4.28
  4. Takanori Morikawa · 27 shared papers, 2013–2023 · strength 2.94
  5. Shuichi Aoki · 19 shared papers, 2013–2026 · strength 2.89
  6. Masahiro Iseki · 18 shared papers, 2017–2026 · strength 2.79
  7. Shimpei Maeda · 19 shared papers, 2017–2026 · strength 2.50
  8. Sohei Satoi · 17 shared papers, 2015–2026 · strength 2.41
  9. Kyohei Ariake · 20 shared papers, 2017–2026 · strength 2.39
  10. Daisuke Douchi · 11 shared papers, 2021–2026 · strength 1.98
  11. Atsushi Masamune · 11 shared papers, 2016–2026 · strength 1.97
  12. Toru Furukawa · 10 shared papers, 2017–2026 · strength 1.69
  13. Tatsuo Hata · 12 shared papers, 2017–2023 · strength 1.39
  14. Koetsu Inoue · 7 shared papers, 2023–2026 · strength 1.35
  15. Takashi Kokumai · 7 shared papers, 2021–2025 · strength 1.21
  16. Tatsuyuki Takadate · 14 shared papers, 2016–2022 · strength 1.20
  17. Mitsuhiro Shimura · 7 shared papers, 2017–2026 · strength 1.19
  18. Daisuke Hashimoto · 6 shared papers, 2025–2026 · strength 1.19
  19. Kenichiro Uemura · 9 shared papers, 2015–2026 · strength 1.13
  20. Satoshi Hirano · 6 shared papers, 2025–2026 · strength 1.13
  21. So Yamaki · 5 shared papers, 2025–2026 · strength 1.01
  22. Shinichi Egawa · 9 shared papers, 2013–2026 · strength 1.00
  23. Kenjiro Okada · 5 shared papers, 2022–2026 · strength 0.90
  24. Yoshifumi Takeyama · 4 shared papers, 2026 · strength 0.89
  25. Kohei Nakata · 4 shared papers, 2025–2026 · strength 0.87

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.